InvestSMART

Lumos Diagnostics Holdings Limited (ASX: LDX) - Announcements

- Current share price for LDX : $0.115

ASX company news and announcements for Lumos Diagnostics Holdings Limited (LDX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Lumos Diagnostics Holdings Limited (LDX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Lumos Diagnostics Holdings Limited (LDX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Lumos Diagnostics Holdings Limited (LDX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$109 1H FY25 Results Investor Briefing Invitation 25 Feb 2025 12:27PM $0.029 $0.115 risen by 296.55%
$109 Q2 FY25 Results Investor Briefing Invitation 5 Feb 2025 9:08AM $0.030 $0.115 risen by 283.33%
$109 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jan 2025 9:02AM $0.040 $0.115 risen by 187.50%
$109 Notification of cessation of securities - LDX 13 Jan 2025 3:57PM $0.039 $0.115 risen by 194.87%
$109 Lumos Partners with MedPro for Sales of FebriDx in the US 13 Jan 2025 9:25AM $0.038 $0.115 risen by 202.63%
$109 Notification of cessation of securities - LDX 9 Jan 2025 9:16AM $0.037 $0.115 risen by 210.81%
$109 Listing Rule 6.22.2 Adjustment to Option Exercise Prices 20 Dec 2024 1:53PM $0.036 $0.115 risen by 219.44%
$109 Application for quotation of securities - LDX 20 Dec 2024 10:17AM $0.036 $0.115 risen by 219.44%
$109 Section 708A Cleansing Statement 20 Dec 2024 10:16AM $0.036 $0.115 risen by 219.44%
$109 Commencement of FebriDx CLIA Waiver Study 19 Dec 2024 3:53PM $0.034 $0.115 risen by 238.24%
$109 Notification regarding unquoted securities - LDX 13 Dec 2024 2:34PM $0.035 $0.115 risen by 228.57%
$109 Change of Director's Interest Notice - DW 10 Dec 2024 8:54AM $0.039 $0.115 risen by 194.87%
$109 Application for quotation of securities - LDX 6 Dec 2024 10:05AM $0.039 $0.115 risen by 194.87%
$109 Section 708A Cleansing Statement 6 Dec 2024 10:04AM $0.039 $0.115 risen by 194.87%
$109 Lumos receives CPT PLA Code for FebriDX in the US 5 Dec 2024 9:50AM $0.031 $0.115 risen by 270.97%
$109 Results of Annual General Meeting 14 Nov 2024 2:33PM $0.030 $0.115 risen by 283.33%
$109 2024 AGM Presentation 14 Nov 2024 8:36AM $0.033 $0.115 risen by 248.48%
$109 AGM Chair Address 14 Nov 2024 8:33AM $0.033 $0.115 risen by 248.48%
$109 Quarterly Activities/Appendix 4C Cash Flow Report 29 Oct 2024 9:26AM $0.041 $0.115 risen by 180.49%
$109 Lumos and BARDA Partnership - Investor Briefing Recording 16 Oct 2024 9:45AM $0.048 $0.115 risen by 139.58%
$109 Cancel - Proposed issue of securities - LDX 14 Oct 2024 12:28PM $0.046 $0.115 risen by 150%
$109 Proposed issue of securities - LDX 14 Oct 2024 11:18AM $0.046 $0.115 risen by 150%
$109 Notice of Annual General Meeting and Proxy Form 14 Oct 2024 10:53AM $0.047 $0.115 risen by 144.68%
$109 Change in substantial holding 11 Oct 2024 3:14PM $0.044 $0.115 risen by 161.36%
$109 Lumos and BARDA Partnership - Investor Presentation 11 Oct 2024 9:21AM $0.045 $0.115 risen by 155.56%

151 - 175 of 544 results

Page 7 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.